Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Obstet Gynaecol Res ; 44(1): 81-86, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29094444

RESUMO

AIM: We aimed to assess the use of metformin (MTF) in the prevention of gestational diabetes mellitus (GDM) in patients with pregestational insulin resistance (PIR). METHODS: A double blind, multicenter, randomized trial was carried out in patients with a history of PIR and pregestational MTF treatment. Groups were allocated either to MTF 1700 mg/day or placebo. Patients were recruited between 12+0 and 15+6 gestational weeks, and treatment was extended until week 36. A multiple logistic regression analysis was applied to determine the relation between the use of metformin and the development of GDM. RESULTS: One hundred and forty one patients were randomized (68 patients in the MTF group and 73 in the placebo group). A total of 30 patients withdrew from the study during follow-up. Administration of MTF was not associated with a decrease in the incidence of GDM as compared to placebo (37.5% vs 25.4%, respectively; P = 0.2). Moreover, MTF administration was associated with a significant increase in drug intolerance as compared to placebo (14.3% vs 1.8%, respectively; P = 0.02). CONCLUSION: The use of MTF is not effective in prevention of GDM in populations with PIR. The use of MTF shows a significantly higher frequency of drug intolerance than placebo.


Assuntos
Diabetes Gestacional/prevenção & controle , Hipoglicemiantes/farmacologia , Resistência à Insulina , Metformina/farmacologia , Falha de Tratamento , Adulto , Método Duplo-Cego , Feminino , Humanos , Hipoglicemiantes/administração & dosagem , Hipoglicemiantes/efeitos adversos , Metformina/administração & dosagem , Metformina/efeitos adversos , Gravidez
3.
Gynecol Obstet Invest ; 77(2): 111-6, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24480896

RESUMO

AIM: To assess the impact that pregestational insulin resistance (PIR) has as a risk factor for preeclampsia (PE). METHODS: Nested case-control study that included patients with PIR and a control group that was randomly selected from pregnancies admitted to the Fetal Medicine Unit between January 2005 and May 2011. Clinical and hemodynamic variables were analyzed by a multiple logistic regression analysis. RESULTS: Of the 13,124 patients admitted during the study period, 119 had a diagnosis of PIR (0.9%). Patients with PIR were older and had a higher body mass index (BMI). PIR was also related to a significantly higher frequency of chronic hypertension (CrHT; 10.1 vs. 2.2%, p < 0.05) and hypothyroidism (5.0 vs. 1.6%, p < 0.05) than in the control group. Moreover, women with PIR were more likely to develop PE (8.4 vs. 4.2%, p < 0.05) and gestational diabetes mellitus (9.2 vs. 2.9%) than the control group. Multivariate analysis showed that maternal age, CrHT and altered uterine artery Doppler sonography during the first and second trimesters were good predictors of PE and that PIR was not. CONCLUSION: Although PIR correlates with PE, conditions related to the latter (CrHT, higher maternal age and increased BMI) may be predominant as risk factors for PE.


Assuntos
Índice de Massa Corporal , Diabetes Gestacional/epidemiologia , Hipertensão/epidemiologia , Hipotireoidismo/epidemiologia , Resistência à Insulina/fisiologia , Pré-Eclâmpsia/epidemiologia , Adulto , Fatores Etários , Estudos de Casos e Controles , Doença Crônica , Feminino , Humanos , Gravidez , Distribuição Aleatória , Fatores de Risco , Ultrassonografia Pré-Natal , Artéria Uterina/diagnóstico por imagem , Artéria Uterina/fisiopatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA